Table of Contents
- What is LITENIMOD SODIUM?
- How is LITENIMOD SODIUM Used?
- Clinical Trial Details
- Eligibility Criteria
- Potential Benefits and Risks
- What to Expect During the Trial
What is LITENIMOD SODIUM?
LITENIMOD SODIUM is an investigational drug being studied for the treatment of glioblastoma, a type of aggressive brain cancer[1]. It belongs to a class of medications called cytokines and immunomodulators, which are substances that can modify or regulate the immune system’s function[1].
The drug is currently being tested in a clinical trial called NAVIG-1, which stands for “New adjuvant vaccine in glioblastoma.” This trial is exploring the use of LITENIMOD SODIUM in combination with other treatments for patients with glioblastoma[1].
How is LITENIMOD SODIUM Used?
In the clinical trial, LITENIMOD SODIUM is administered as a solution for injection. The drug is given through subcutaneous injections, which means it’s injected just under the skin, typically in the shoulder area[1].
The trial is testing LITENIMOD SODIUM in combination with other treatments, including:
- Peptides (small proteins) that may help stimulate the immune system
- Temozolomide, a chemotherapy drug commonly used for glioblastoma
- Radiation therapy
Clinical Trial Details
The NAVIG-1 trial is a Phase 1/2a study, which means it’s an early-stage trial designed to test the safety and effectiveness of the treatment[1]. The trial has two main parts:
- Phase 1: This phase aims to determine the safest and most effective dose of the treatment. Researchers will test different dose levels of the peptides (50, 100, or 250 micrograms) combined with a fixed dose of 1mg of LITENIMOD SODIUM[1].
- Phase 2a: In this phase, researchers will use the dose selected in Phase 1 to further study the treatment’s effectiveness and safety[1].
Eligibility Criteria
To participate in this trial, patients must meet certain criteria. Some key eligibility requirements include:
- Age between 18 and 75 years old
- Confirmed diagnosis of glioblastoma
- Previous treatment with radiation therapy and temozolomide
- Adequate organ function
- Specific genetic markers (HLA-A2 positive and PTPRZ1 expression in the tumor)[1]
There are also several factors that may exclude a patient from participating, such as certain medical conditions, pregnancy, or recent use of other experimental treatments[1].
Potential Benefits and Risks
As with any experimental treatment, there are potential benefits and risks to consider:
Potential Benefits:
- Improved survival rates for glioblastoma patients
- Potential to slow or stop tumor growth
- Contribution to scientific knowledge about glioblastoma treatment
Potential Risks:
- Side effects from the treatment, which may range from mild to severe
- Possibility that the treatment may not be effective
- Time commitment and potential discomfort from trial procedures
What to Expect During the Trial
Participants in the NAVIG-1 trial can expect the following:
- Regular medical check-ups and blood tests to monitor safety and immune responses[1]
- Brain MRI scans to assess tumor progression[1]
- Quality of life assessments using questionnaires[1]
- Treatment administration through subcutaneous injections
- Long-term follow-up to assess overall survival and long-term effects of the treatment
It’s important to note that participation in clinical trials is voluntary, and patients can withdraw at any time. If you’re interested in learning more about this trial or other treatment options for glioblastoma, it’s crucial to discuss with your healthcare provider to determine the best course of action for your individual situation.
